Drug Profile

YY 2201

Alternative Names: YY-2201

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu YaYao Biotechnology
Class Amides; Amines; Antineoplastics; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Small molecules
Mechanism of Action ATR protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

16 May 2025 Jiangsu YaYao Biotechnology plans a early phase I trial for Solid tumours (Late stage disease, First line therapy) in May 2025 (PO, Tablet) (NCT06976931)
03 Mar 2025 Preclinical trials in Solid tumours in China (PO)
03 Mar 2025 US FDA approves IND application for YY 2201 in Solid tumours

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com